Multi-Target

PARP1 structure and function

Beyond PARP1 Single-Target Inhibitors–Combined Therapy Reveals More Possibilities

In late 2014, the PARP inhibitor Olaparib was approved to treat ovarian cancer with BRCA mutations. Since then, research in the field of PARP has received extensive attention, especially in […]